Japanese 
English 
TOKYO, Japan, 5th Jan. 2022: — PRISM BioLab, a Japan based biotechnology company with a proprietary peptide mimetic small molecule drug discovery platform, today announced it has entered into a multitarget research collaboration and licensing agreement with Roche and Genentech, a member of the Roche Group. Read Full Press Release
アーカイブ: ニュース
エーザイとPRISM BioLab共同創製のCBP/β-catenin阻害剤E7386について、臨床におけるPOC（Proof of Concept：創薬概念の検証）を達成
エーザイ株式会社と株式会社PRISM BioLabは、このたび、両社が共同で創製した中分子化合物であるCREB-binding protein （CBP）/β-catenin阻害剤E7386について、臨床におけるPOC（Proof of Concept：創薬概念の検証）を達成したことをお知らせします。
株式会社PRISM BioLab、エーザイ株式会社より資金調達
PRISM BioLab, the Japan based biotechnology company with proprietary small molecule drug discovery technology ”PepMetics®”, today announced that it has raised ¥100 million in Series C funding through a third-party allotment to Eisai Co. Ltd. on October 14. PRISM has completed the series C financing of 1.4 billion yen in total and aims to achieve...
当社のペプチド模倣化合物に関する論文がACS Omegaに掲載されました
本稿では、ペプチド模倣化合物と実際のペプチドの構造との類似度を評価する手法を開発し、当社の化合物が優位性を示すことが述べられています。
Visualized and Quantitative Conformational Analysis of Peptidomimetics
ACS omega, 6(40), 26601-26612 (2021)
Visualized and Quantitative Conformational Analysis of Peptidomimetics
ACS omega, 6(40), 26601-26612 (2021)
Takashima, Hajime; Yoshimori, Atsushi; Honda, Eiji; Taguri, Tomonori; Ozawa, Jun; Kasai, Masaji; Shuto,
Satoshi; Takehara, Dai
株式会社PRISM BioLab、13億円のシリーズC資金調達を実施
PRISM BioLab, the Japan based biotechnology company with proprietary small molecule drug discovery technology ”PepMetics®”, today announced that it has raised a total of ¥1.3 billion in Series C funding on August 27. Read Full Press Release
Generalized-ensemble method study: A helix-mimetic compound inhibits protein-protein interaction by long-range and short-range intermolecular interactions
Journal of Computational Chemistry, 42(14), 956-969 (2021)
Higo, Junichi; Takashima, Hajime; Fukunishi, Yoshifumi; Yoshimori, Atsushi
E7386, a selective inhibitor of the interaction between β-catenin and CBP, exerts antitumor activity in tumor models with activated canonical wnt signaling
Cancer Research, 81(4), 1052-1062 (2021)
Yamada, Kazuhiko; Hori, Yusaku; Inoue, Satoshi; Yamamoto, Yuji; Iso, Kentaro; Kamiyama, Hiroshi; Yamaguchi, Atsumi; Kimura, Takayuki; Uesugi, Mai; Ito, Junichi; Matsuki, Masahiro; Nakamoto, Kazutaka; Harada, Hitoshi; Yoneda, Naoki; Takemura, Atsushi; Kushida, Ikuo; Wakayama, Naomi; Kubara, Kenji; Kato, Yu; Semba, Taro; Yokoi, Akira; Matsukura, Masayuki; Odagami, Takenao; Iwata, Masao; Tsuruoka, Akihiko; Uenaka, Toshimitsu; Matsui, Junji; Matsushima, Tomohiro; Nomoto, Kenichi; Kouji, Hiroyuki; Owa, Takashi; Funahashi, Yasuhiro; Ozawa, Yoichi
Anti-tumor activity of the small molecule inhibitor PRI-724 against β-catenin-activated hepatocellular carcinoma
Anticancer Research, 40, 5211-5219 (2020)
Gabata, Ryosuke; Harada, Kenichi; Mizutani, Yuki; Ouchi, Hirofumi; Yoshimura, Kaori; Sato, Yasunori; Kitao, Azusa; Kimura, Kiminori; Kouji, Hiroyuki; Miyashita, Tomoharu; Tajima, Hidehiro; Ohta, Tetsuo
β-catenin signaling inhibitors ICG-001 and C-82 improve fibrosis in preclinical models of endometriosis
Scientific Reports, 9(1), 20056 (2019)
Hirakawa, Tomoko; Nasu, Kaei; Miyabe, Saori; Kouji, Hiroyuki; Katoh, Akira; Uemura, Naoto; Narahara, Hisashi